C/EBPα Is Up-regulated in a Subset of Hepatocellular Carcinomas and Plays a Role in Cell Growth and Proliferation
Background & Aims
C/EBPα (cebpa) is a putative tumor suppressor. However, initial results indicated that cebpa was up-regulated in a subset of human hepatocellular carcinomas (HCCs). The regulation and function of C/EBPα was investigated in HCC cell lines to clarify its role in liver carcinogenesis.
Methods
The regulation of C/EBPα expression was studied by quantitative reverse transcription–polymerase chain reaction (qRT-PCR), Western blotting, immunohistochemistry, methylation-specific PCR, and chromatin immunoprecipitation assays. C/EBPα expression was knocked-down by small interfering RNA or short hairpin RNA. Functional assays included colony formation, methylthiotetrazole, bromodeoxyuridine incorporation, and luciferase-reporter assays.
Results
Cebpa was up-regulated at least 2-fold in a subset (approximately 55%) of human HCCs compared with adjacent nontumor tissues. None of the up-regulated samples were positive for hepatitis C infection. The HCC cell lines Hep3B and Huh7 expressed high, PLC/PRF/5 intermediate, HepG2 and HCC-M low levels of C/EBPα, recapitulating the pattern of expression observed in HCCs. No mutations were detected in the CEBPA gene in HCCs and cell lines. C/EBPα was localized to the nucleus and functional in Hep3B and Huh7 cells; knocking-down its expression reduced target-gene expression, colony formation, and cell growth, associated with a decrease in cyclin A and CDK4 concentrations and E2F transcriptional activity. Epigenetic mechanisms including DNA methylation, and the binding of acetylated histone H3 to the CEBPA promoter–regulated cebpa expression in the HCC cells.
Conclusions
C/EBPα is up-regulated in a subset of HCCs and has growth-promoting activities in HCC cells. Novel oncogenic mechanisms involving C/EBPα may be amenable to epigenetic regulation to improve treatment outcomes.
Keywords: C/EBPα, Hepatocellular Carcinoma, Growth Promotion, Epigenetic Regulation
Abbreviations used in this paper: 5-aza dC, 5-aza-2′-deoxycytidine, ChIP, chromatin immunoprecipitation, HBV, hepatitis B, HCC, hepatocellular carcinoma, HCV, hepatitis C, HDAC, histone deacetylase, LY, LY294002, OA, okadaic acid, PI3K, phosphoinositol-3 kinase, qRT-PCR, quantitative reverse-transcription–polymerase chain reaction, shRNA, short hairpin RNA, siRNA, small interfering RNA, TSA, trichostatin A
To access this article, please choose from the options below
Conflicts of interest The authors disclose no conflicts.
Funding This work is supported by grants from the Singapore National Medical Research Council (NMRC/1068/2006 and NMRC/1211/2009).
PII: S0016-5085(10)00484-1
doi:10.1053/j.gastro.2010.03.051
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

